The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
Saved in:
Main Authors: | Pankaj Jariwala, Kartik Jadhav |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c83fceb969274be9a498b3301be5ddb4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
by: Pankaj Jariwala, et al.
Published: (2021) -
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
by: M Rizzo, et al.
Published: (2020) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021) -
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
by: M Rizzo, et al.
Published: (2020) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021)